Figure 7.
Anti–IGSF9-DXd–treated the advanced AML models. A total of 1 × 106 THP-1-luc cells are injected into NSG mice via the tail vein. (A) At 15 days after injection administration, treatment is initiated using isotype control, anti-IGSF9, DXd, and anti–IGSF9-DXd, and administered every 4 days. (B,C) The bioluminescence imaging is used to detect disease progression, and the survival curve is drawn. (D) H&E staining is used to observe the tumors in lungs and liver, and tissue structure and cell morphology of kidney, heart, and brain.

Anti–IGSF9-DXd–treated the advanced AML models. A total of 1 × 106 THP-1-luc cells are injected into NSG mice via the tail vein. (A) At 15 days after injection administration, treatment is initiated using isotype control, anti-IGSF9, DXd, and anti–IGSF9-DXd, and administered every 4 days. (B,C) The bioluminescence imaging is used to detect disease progression, and the survival curve is drawn. (D) H&E staining is used to observe the tumors in lungs and liver, and tissue structure and cell morphology of kidney, heart, and brain.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal